Balixafortide

DRACPC ID  DRACPC0050

Active Ingredients   Balixafortide

Description  An orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with receptor binding and hematopoietic stem cell-mobilization activities. Balixafortide binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into blood. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.

Synonyms  POL6326; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his Cyclic (2->9)-disulfide; Balixafortide

Type  Biotech

Disease  Breast Cancer

Classification

  

CXCR4 inhibitor Peptide and derivative Cyclic

Structure Information


Molecular Formula  C84H118N24O21S2

Molecular Weight  1864.1

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  3-[(1R,4S,7S,10S,16S,22R,25S,28S,31S,34R,37S,40S,43S,46R,52S,55S)-25-(4-aminobutyl)-43-(2-aminoethyl)-40-(3-carbamimidamidopropyl)-55-(hydroxymethyl)-10,31,37-tris[(4-hydroxyphenyl)methyl]-7-(1H-imidazol-5-ylmethyl)-4,52-dimethyl-3,8,11,17,23,26,29,32,35,38,39,42,45,51,54,57-hexadecaoxo-59,60-dithia-2,5,6,9,12,18,24,27,30,33,36,41,44,50,53,56-hexadecazapentacyclo[32.23.4.012,16.018,22.046,50]henhexacontan-28-yl]propanamide

InChI  InChI=1S/C84H118N24O21S2/c1-44-70(116)102-62-41-130-131-42-63(77(123)98-57(35-46-14-20-50(110)21-15-46)69(115)68(114)53(10-5-31-91-84(88)89)94-73(119)56(28-30-86)97-79(125)64-11-6-32-106(64)81(127)45(2)93-76(122)61(40-109)101-78(62)124)103-74(120)58(36-47-16-22-51(111)23-17-47)99-72(118)55(26-27-67(87)113)95-71(117)54(9-3-4-29-85)96-80(126)65-12-7-33-107(65)83(129)66-13-8-34-108(66)82(128)60(37-48-18-24-52(112)25-19-48)100-75(121)59(105-104-44)38-49-39-90-43-92-49/h14-25,39,43-45,53-66,104-105,109-112H,3-13,26-38,40-42,85-86H2,1-2H3,(H2,87,113)(H,90,92)(H,93,122)(H,94,119)(H,95,117)(H,96,126)(H,97,125)(H,98,123)(H,99,118)(H,100,121)(H,101,124)(H,102,116)(H,103,120)(H4,88,89,91)/t44-,45-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64+,65+,66-/m0/s1

InChI_Key OYWQJZAVFWOOBF-WBMPNIIXSA-N

SMILES  C[C@@H]1NN[C@H](C(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]4CSSC[C@@H](C(N[C@H](C(N[C@H](C(N5CCC[C@@H]5C(N[C@H](C(N[C@H](C(C([C@@H](NC4=O)CC6=CC=C(C=C6)O)=O)=O)CCCNC(N)=N)=O)CCN)=O)=O)C)=O)CO)=O)NC1=O)=O)CC7=CC=C(C=C7)O)=O)CCC(N)=O)=O)CCCCN)=O)=O)=O)CC8=CC=C(C=C8)O)=O)CC9=CN=CN9

External Codes


PubChem CID  138752609

DrugBank Accession Number  DB15370

NCI Thesaurus Code  C91094  

UNII  PRC974M49B   GSRS

CAS  1051366-32-5



Drug approval


Drug indication
    Investigated for use/treatment in locally recurrent/metastatic/advanced breast cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT04826016 A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer Advanced Breast Cancer Phase 1/2 Treatment
NCT01837095 A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer Metastatic Breast Cancer Phase 1 Treatment
NCT01413568 A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies Acute Myeloid Leukemia in Remission; Adult Acute Lymphoblastic Leukemia in Remission; Chronic Myelogenous Leukemia (CML); Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission; Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM); Myelodysplastic Syndrome (MDS); Myeloproliferative Disorders Phase 1/2 Treatment
NCT03786094 An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Metastatic Breast Cancer; Locally Recurrent Breast Cancer Phase 3 Treatment
NCT01905475 CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction Large Reperfused ST-Elevation Myocardial Infarction Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.